Sarepta Therapeutics (SRPT) Stock
Biotech developing genetic medicines for rare muscular dystrophy. Here's the price, business snapshot, and what's worth knowing about Sarepta Therapeutics in August 2026.
Sarepta Therapeutics (SRPT) is a US‑based biotechnology company focused on genetic medicines for rare neuromuscular conditions, principally Duchenne muscular dystrophy (DMD). Its portfolio includes exon‑skipping oligonucleotides with prior regulatory approvals and a developing gene‑therapy pipeline aimed at restoring dystrophin expression. The company’s clinical updates, regulatory interactions and manufacturing progress tend to drive short‑term share‑price moves. With a market capitalisation of about $2.44 billion, Sarepta is a small‑to‑mid‑cap biotech where R&D outcomes heavily influence valuation. Investors should note high development costs, potential for binary clinical outcomes and ongoing debates about clinical efficacy in some programmes. Commercial revenues exist but remain modest relative to R&D expenditure, so partnerships and successful trial readouts are key. This content is educational only and not personal financial advice; biotech stocks can be volatile and may suit only investors with a higher tolerance for risk and a longer time horizon.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Sarepta's stock, with a target price indicating significant potential growth.
Financial Health
Sarepta Therapeutics is performing well, showing strong revenue, profit margins, and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory decisions can move the shares sharply; successful trials may materially change the outlook, though outcomes are uncertain.
Binary Outcome Risk
Many programmes face all‑or‑nothing trials and manufacturing hurdles, so single events can cause large share‑price swings and volatility.
Commercial & Partnerships
Revenue growth depends on market uptake, payer coverage and collaborations; commercial progress matters alongside science, yet sales may lag R&D spend.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
